Abstract 408P
Background
Glioblastoma (GBM) is one of the most common malignant primary brain tumours, which accounts for 60-70% of all glioma. Conventional diagnosis and post-operation treatment plan for glioblastoma is mainly based on the identification of tumor cells on haematoxylin and eosin stained (H&E) histopathological slides by both experienced medical technologist and pathologist. The recent development of digital whole slide scanners allows the histopathological image analysis feasible. This study aimed to build an image feature based model using histopathology whole slide images to differentiate patients with GBM from healthy control (HC).
Methods
628 H&E images were collected from 30 GBM patients, obtained from public database the Cancer Image Archive. Another 554 images were collected from 30 HC. 22 Gray level Co-occurrence Matrix (GLCM) image features were retrieved from the collected images by an in-house developed software. Both the GBM and HC groups were divided into a training and a validation group on 70:30 basis. A random forest algorithm was used to build the model using training set, and validated by the validation set by R software.
Results
The receiver operating characteristics (ROC) curve showed that the average class and overall accuracy achieved 94.6%. The area under the curve (AUC) was 0.98, with sensitivity of 94.1% and sensitivity of 95.1%.
Conclusions
The machine learning model can accurately differentiate GBM from HC in histopathology whole slide imaging. The application can be fully automatic and it is practical in applying for GBM screening.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
College Research Grant (CRG) - Tung Wah College.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
440P - Targeting KRAS<sup>G12C</sup>: Repurposing of potential therapeutics for the treatment of pancreatic ductal adenocarcinoma (PDAC)
Presenter: EVA RAHMAN KABIR
Session: Poster viewing 06
441P - Malignant diseases diagnosed in people living with HIV in Japan
Presenter: Kenju Ando
Session: Poster viewing 06
442P - Dose intensity and tolerance of modified FOLFIRINOX in patients with advanced cancer
Presenter: Tejaswini Adadadara
Session: Poster viewing 06
444P - Incidence of cancer diagnosis and cancer care before and after the COVID-19 pandemic in French Polynesia TEAHUPOO study
Presenter: Elodie HIRIGOYEN
Session: Poster viewing 06
445P - Development of a simple and objective prognostication model in patients with advanced solid malignant tumor treated with immune checkpoint inhibitors: A pan-cancer analysis
Presenter: Yuto Matsushita
Session: Poster viewing 06
446P - Impact of previous immunotherapy on chemotherapy efficacy in metastatic melanoma
Presenter: Meiyu Fang
Session: Poster viewing 06
447P - Clinical characteristics of 21 patients with type 1 diabetes mellitus related to immune checkpoint inhibitors
Presenter: Haruna Kameoka
Session: Poster viewing 06
448P - Prevalence of thyroid dysfunction, diabetes, and impact of palliative chemotherapy in advanced metastatic cancer patients: Prospective data from LMIC
Presenter: Amit Sehrawat
Session: Poster viewing 06
449P - The study of androgen receptor status in triple negative breast cancer patients at Medical Oncology Department, Yangon General Hospital (YGH)
Presenter: Khin Mu
Session: Poster viewing 06
450P - Are grade III well-differentiated neuroendocrine tumours a unique clinic-pathological entity?
Presenter: Jahnavi Kalvala
Session: Poster viewing 06